Wells Fargo’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wells Fargo’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$122M	Hold	370,000	–	–	0.02%	556
2025 Q4	$147M	Buy	370,000 +350,000	+1,750%	+$155M	0.03%	479
2025 Q3	$9.12M	Hold	20,000	–	–	﹤0.01%	2086
2025 Q2	$6.52M	Hold	20,000	–	–	﹤0.01%	2265
2025 Q1	$5.4M	Hold	20,000	–	–	﹤0.01%	2351
2024 Q4	$4.71M	Buy	+20,000	New	+$5.26M	﹤0.01%	2490
2017 Q2	–	Sell	-126,600	Closed	-$332K	–	6196
2017 Q1	$332K	Buy	126,600 +95,100	+302%	+$4.4M	﹤0.01%	4516
2016 Q4	$31K	Buy	+31,500	New	+$1.32M	﹤0.01%	5511
2015 Q2	–	Sell	-56,100	Closed	-$524K	–	6319
2015 Q1	$524K	Sell	56,100 -1,900	-3%	-$193K	﹤0.01%	3912
2014 Q4	$469K	Buy	+58,000	New	+$5.37M	﹤0.01%	3983
2014 Q3	–	Sell	-20,000	Closed	-$61K	–	6158
2014 Q2	$61K	Sell	20,000 -80,000	-80%	-$4.75M	﹤0.01%	4888
2014 Q1	$67K	Sell	100,000 -5,000	-5%	-$387K	﹤0.01%	4827
2013 Q4	$562K	Buy	+105,000	New	+$6.26M	﹤0.01%	3746

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo's ALNY Position: Q1 2026 in Review

Wells Fargo increased its Alnylam Pharmaceuticals (ALNY) stake by 33% in Q1 2026, buying an estimated $29M and bringing the position to 342,763 shares worth $113M. The position accounts for 0.02% of the portfolio, ranked #585.

Wells Fargo first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $128M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Wells Fargo held 342,763 shares of Alnylam Pharmaceuticals worth $113M as of Q1 2026.
Wells Fargo bought 85,123 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $29M.
Alnylam Pharmaceuticals made up 0.02% of Wells Fargo's portfolio in Q1 2026, its #585 holding.
Wells Fargo first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's Alnylam Pharmaceuticals position peaked at $128M in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.